Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 18 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Petanidis, Savvas [Clear All Filters]
(2024).
Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery..
Pharmaceutics. 15(10),
(2023). Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization..
Front Immunol. 14, 1325360.
(2023). Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy..
Front Oncol. 12, 1042125.
(2022). Epigenetic editing and tumor-dependent immunosuppressive signaling in head and neck malignancies..
Oncol Lett. 23(6), 196.
(2022). Molecular and Immune Phenotypic Modifications during Metastatic Dissemination in Lung Carcinogenesis..
Cancers (Basel). 14(15),
(2022).
(2022). Kras-driven intratumoral heterogeneity triggers infiltration of M2 polarized macrophages via the circHIPK3/PTK2 immunosuppressive circuit..
Sci Rep. 11(1), 15455.
(2021). Treg-dependent immunosuppression triggers effector T cell dysfunction via the STING/ILC2 axis..
Clin Immunol. 222, 108620.
(2021). Carboplatin chemoresistance is associated with CD11b/Ly6C myeloid release and upregulation of TIGIT and LAG3/CD160 exhausted T cells..
Mol Immunol. 118, 99-109.
(2020). Connection between PD-L1 expression and standardized uptake value in NSCLC: an early prognostic treatment combination..
Expert Rev Respir Med.
(2020). Dual photothermal MDSCs-targeted immunotherapy inhibits lung immunosuppressive metastasis by enhancing T-cell recruitment..
Nanoscale. 12(13), 7051-7062.
(2020). Exosomal lncRNA PCAT-1 promotes Kras-associated chemoresistance via immunosuppressive miR-182/miR-217 signaling and p27/CDK6 regulation..
Oncotarget. 11(29), 2847-2862.
(2020). Pleurodesis and Immunotherapy in NSCLC; Medical Thoracoscopy or VATS?.
J Cancer. 11(6), 1606-1613.
(2020). Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer..
J Cancer. 11(11), 3407-3415.
(2020).
(2019).
Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer..
J Cancer. 8(18), 3648-3656.
(2017).
(2015).